



**THE FOUNDATION  
FOR SECURE  
MARKETS**

**#48390**

**Date:** March 04, 2021

**Subject:** Adjusted Viracta Therapeutics, Inc. - Cash In Lieu Settlement  
Adjusted Option Symbol: VIRX1

Adjusted Viracta Therapeutics, Inc. (formerly Sunesis Pharmaceuticals, Inc.) options were previously adjusted on September 3, 2020 and again on February 25, 2021 (See OCC Information Memo's #47530 and #48347). The new deliverable became 1) 2 Viracta Therapeutics, Inc. (VIRX) Common Shares, and 2) Cash in lieu of approximately 0.85714 fractional VIRX shares. Only settlement of the cash portion of VIRX1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of \$13.04 per whole VIRX share will be used to determine the cash in lieu amount at a rate of 0.85714. Accordingly, the cash in lieu amount is:

$$0.85714 \times \$13.04 = \$11.18 \text{ per VIRX1 Contract}$$

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of February 25, 2021 through March 4, 2021, to deliver the appropriate cash amount.

Terms of the VIRX1 options are as follows:

**New Deliverable**

**Per Contract:** 1) 2 Viracta Therapeutics, Inc. (VIRX) Common Shares  
2) \$11.18 Cash

**Strike Prices:** Unchanged

**CUSIP:** VIRX: 92765F108

**Multiplier:** 100 (i.e., a premium of 1.50 yields \$150)

**Settlement**

The VIRX component of VIRX1 exercise/assignment activity from February 25, 2021 through March 3, 2021, has settled through National Security Clearing Corporation (NSCC). The \$11.18 cash amount will be settled by OCC.

**Pricing**

The underlying price for VIRX1 will be determined as follows:

$$\text{VIRX1} = 0.02 (\text{VIRX}) + 0.1118$$

For example, if VIRX closes at 12.68, the VIRX1 price would be calculated as follows:

$$\text{VIRX1} = 0.02 (12.68) + 0.1118 = 0.37$$

### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email [investorservices@theocc.com](mailto:investorservices@theocc.com). Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).